Condition: Gaucher Disease Type 1 · Sponsor: Spur Therapeutics
This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT/SRT.
This description comes directly from the study's public registry record.
Spur Clinical Trials Contact · +44 (0)1438 906870 · clinicaltrials@spurtherapeutics.com
Always discuss trial participation with your own doctor first.
| Kaiser Permanente - CA | Los Angeles, California, United States | Recruiting |
| UCLA Health | Los Angeles, California, United States | Not Yet Recruiting |
| University of California, San Francisco (UCSF) | San Francisco, California, United States | Recruiting |
| University of Colorado Anschutz | Aurora, Colorado, United States | Recruiting |
| Emory Healthcare | Atlanta, Georgia, United States | Not Yet Recruiting |
| University of Iowa Health Care | Iowa City, Iowa, United States | Not Yet Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Not Yet Recruiting |
| NYU Langone Health | New York, New York, United States | Not Yet Recruiting |
| Columbia University | New York, New York, United States | Not Yet Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Not Yet Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223944